Sudeep Pharma: Powering Growth with Specialty Ingredients and Battery Materials

Sudeep Pharma Limited, a prominent player in the specialty chemicals sector, has reported a robust financial performance for the third quarter and nine months ended December 31, 2025 (Q3 FY26 and 9MFY26). The company's strategic focus on diversification and innovation is clearly yielding results, positioning it for sustained growth in high-barrier markets.

For Q3 FY26, Sudeep Pharma recorded a total income of INR 179.2 crores, marking a significant 52% year-on-year growth. This strong top-line expansion translated into impressive profitability, with EBITDA surging by 60% year-on-year to INR 66.8 crores, and Profit After Tax (PAT) climbing by an even more remarkable 66% year-on-year to INR 47.7 crores. The EBITDA margin for the quarter stood at a healthy 37.3%, while the PAT margin was 26.6%. The nine-month performance further underscores this positive trajectory, with total income reaching INR 482.1 crores, a 38% increase over the previous year. EBITDA for 9MFY26 grew by 33% to INR 181.5 crores, and PAT increased by 33% to INR 125.7 crores.

The company's revenue breakdown for 9MFY26 highlights the growing importance of its specialty ingredients segment, which contributed 43% of the total revenue. The pharmaceutical, food, and nutrition segment accounted for the remaining 57%. Geographically, exports played a dominant role, contributing 62% of the revenue in both Q3 FY26 and 9MFY26, with domestic business making up 38%. Management noted strong momentum across regions, driven by robust underlying demand and strategic investments.

Strategic Expansion and Diversification

Sudeep Pharma is actively pursuing multiple strategic initiatives to fuel its next phase of growth. A significant development is its entry into the battery materials sector with the groundbreaking ceremony for its Battery Chemicals Plant at Dahej, Gujarat. This plant, with a planned Phase I capacity of 25,000 MT per annum, will produce battery-grade iron phosphate, positioning Sudeep Pharma as a crucial non-Chinese supplier for the rapidly expanding EV and energy storage markets. The total project cost for a 100,000-ton capacity is estimated at INR 550-600 crores, with Phase I commissioning expected by early CY27. The company has already upgraded its existing iron phosphate capacity to 5,000 MT to cater to initial commercial orders and is actively engaging with 34 customers, with 70% having approved samples.

Concurrently, Sudeep Pharma is expanding its core pharmaceutical, food, and nutrition business with a new greenfield manufacturing facility in Nandesari. This INR 150 crore project, expected to be commissioned by Q4 FY26, will add 51,200 MT of annual capacity. It will focus on higher-value molecules like gluconates, glycinates, and citrates, which are anticipated to enhance margin profiles. While customer approvals will take 6-12 months post-commissioning, significant revenue contribution is expected from H2 FY27 and more substantially from FY28.

Inorganic Growth and Innovation

Inorganic growth remains a key pillar of Sudeep Pharma's strategy. The acquisition of 85% ownership in NSS (Nutrition Supplies Services) in May 2025 has been smoothly integrated. NSS specializes in manufacturing vitamin and mineral blends for infant nutrition and critical care segments, strengthening Sudeep Pharma's formulation capabilities and expanding its footprint in regulated European markets. NSS, with a 7,500 MT manufacturing capacity, is expected to contribute meaningfully to growth over the next two years.

Innovation is also at the forefront, particularly with the expansion of the company's indigenous liposomal chemistry platform. Initially focused on minerals like iron and vitamin C, this technology is being extended to other nutrients such as DHA for brain health and glutathione for cosmeceutical applications. This diversification into new end applications is expected to generate revenue from H2 FY27, with more significant contributions in FY28, further enhancing the product portfolio and market reach.

Outlook and Investor Confidence

Sudeep Pharma's management expressed confidence in sustaining the current growth momentum, driven by deeper customer engagement, expanding global reach, and capacity additions. The company's strategic positioning as a reliable, non-Chinese supplier for battery materials, coupled with its robust regulatory-certified infrastructure and diversified product portfolio, underpins its ability to create long-term, sustainable value. The growing global emphasis on health and wellness continues to fuel demand for nutritional supplements, reinforcing the company's strong market position. With disciplined capital allocation and a clear roadmap for execution, Sudeep Pharma is well-positioned for its next phase of growth, aiming to capitalize on emerging industry trends and strengthen its leadership in specialty ingredients.